Becton Dickinson Accused of Abusing Monopoly Power in Hernia Mesh Market

Small-cap firm TELA Bio alleges Becton Dickinson abused monopoly power in the U.S. hernia mesh market, blocking competition, raising costs, and limiting treatment choices. TELA Bio argues Becton Dickinson used restrictive contracting practices to exclude its lower-cost product, OviTex, from hospitals nationwide. The lawsuit seeks damages, injunctive relief, and other remedies to restore competition and expand patient choice in the hernia mesh market.